Avenue therapeutics announces first patient dosed in phase 1b/2a clinical trial of aj201 for the treatment of spinal and bulbar muscular atrophy (kennedy's disease)

Miami, july 27, 2023 (globe newswire) -- avenue therapeutics, inc. (nasdaq: atxi) (“avenue” or the “company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that the first patient has been dosed in the phase 1b/2a clinical trial of aj201 for the treatment of spinal and bulbar muscular atrophy (“sbma”), also known as kennedy's disease. a recent study used genetic analysis to estimate disease prevalence of 1:6,887 males.1 aj201 is currently the lead drug candidate in the clinic for sbma and enrollment in the trial is expected to be complete by the end of 2023 or early 2024 with potential topline data in 2024.
ATXI Ratings Summary
ATXI Quant Ranking